Drug Profile
Research programme: urinary incontinence - Bayer/Millennium
Alternative Names: Urinary incontinence research programme - Bayer/MilleniumLatest Information Update: 29 Jun 2006
Price :
$50
*
At a glance
- Originator Bayer; Millennium Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Urinary incontinence
Most Recent Events
- 31 Oct 2003 Bayer and Millennium have extended their research collaboration agreement
- 21 Sep 2001 Preclinical development for Urinary incontinence in Germany (Unknown route)
- 21 Sep 2001 Preclinical development for Urinary incontinence in USA (Unknown route)